Christopher W. Ogden
SVP, CFO & SecretaryMr. Christopher W. Ogden, also known as Chris, is Chief Financial Officer at CytomX Therapeutics, Inc since June 15, 2024 and serves as SVP and Secretary. Mr. Ogden served as Senior Vice President of Finance & Accounting of CytomX Therapeutics, Inc. until June 15, 2024 and served as its Interim Principal Accounting Officer since February 14, 2022 until September 24, 2022. Mr. Ogden joined CytomX in August of 2021 as Vice President, Finance and Accounting and has since served in roles of increasing responsibility spanning finance, accounting, investor relations, capital raising, information technology and facilities. Mr. Ogden served as the Chief Financial Officer of the Lilly Diabetes division at Eli Lilly and Company (“Eli Lilly”) from May 2021 to August 2021. While at Eli Lilly, Mr. Ogden also held the positions of Senior Director, Chief Financial Officer and Treasurer of Lilly del Caribe, from April 2018 to May 2021, the Director of Investor Relations from June 2016 to April 2018 and the Financial Director of the U.S. Diabetes division, from January 2014 to May 2016. Mr. Ogden received his B.A. in economics from Wabash College and his M.B.A. from Harvard Business School.
Positions
- Company NameCytomX Therapeutics, Inc.Stock CodeCTMXPositionSVP, CFO & SecretaryColleagues
- SASean A. McCarthyChairman & CEO
- RLRachael LesterChief Business Officer & Senior VP
- MPMarcia P. BelvinSenior VP & Chief Scientific Officer
- AVAlejandra Veronica CarvajalChief Legal Officer
- MPMatthew P. YoungLead Independent Director
- JRJames R. MeyersIndependent Director
- HEHalley E. GilbertIndependent Director
- WMW. Michael KavanaughMember of Scientific Advisory Board
